全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2018 

Methylation of O6-methylguanine DNA methyltransferase promoter is a predictive biomarker in Chinese melanoma patients treated with alkylating agents

DOI: 10.21037/21588

Full-Text   Cite this paper   Add to My Lib

Abstract:

Melanoma is a highly aggressive skin cancer with high treatment resistance. Although the U.S. Food and Drug Administration (FDA) has approved various targeted therapies for melanoma which includes BRAF and MEK mutation inhibitors, based on the improved responses observed among patients harboring such mutations, many patients acquire therapeutic resistance and therefore do not achieve persistent, long-term responses (1). Antibodies specific for immune checkpoints, such as those targeting CTLA-4 or the PD1/PDL1 interaction, have also been approved by the FDA and have become a standard of care for patients with unresectable or metastatic melanoma; however, these therapeutic antibodies provide benefits to only some patients (2)

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133